CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.28: grey zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.17%Below 5Y avg (0.44%)
Annual Rate
INR 0.40Paid semi-annual
Payout Ratio
172.8%High
Last Ex-Dividend
Sep 2, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
28.88BINR303.36M · vs all stocks (USD)
Trailing P/E
302.06xRevenue (TTM)
16.99BINR178.45M · vs all stocks (USD)
Profit Margin
0.59%Beta
0.3690xvs all stocks
52-Week Change
-31.80%vs all stocks
Forward Annual Dividend Yield
0.17%vs all stocks
Market Capitalization
28.88BINR303.36M · vs all stocks (USD)
Enterprise Value
30.20BINR317.20M · vs all stocks (USD)
Trailing P/E
302.06xForward P/E
25.98xPrice to Sales (TTM)
1.75xPrice to Book (MRQ)
2.50xEnterprise to Revenue
1.78xEnterprise to EBITDA
13.33xGross Margin
58.10%Profit Margin
0.59%Operating Margin
-10.67%Return on Assets (TTM)
1.98%Return on Equity (TTM)
0.84%Revenue (TTM)
16.99BINR178.45M · vs all stocks (USD)
Revenue per Share (TTM)
137.75INRUpdated Jul 17, 2026Quarterly Revenue Growth
-29.70%Gross Profit (TTM)
8.68BINR91.22M · vs all stocks (USD)
EBITDA (TTM)
2.33BINR24.44M · vs all stocks (USD)
Net Income (TTM)
101.00MINR1.06M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.00%Operating Cash Flow (TTM)
3.05BINR32.02M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.21BINR12.74M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4000INRUpdated Jul 17, 2026Forward Annual Dividend Yield
0.17%vs all stocks
Trailing Annual Dividend Rate
1.00INRUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.43%vs all stocks
5-Year Average Dividend Yield
0.44%vs all stocks
Payout Ratio
172.84%Revenue
16.95BINRFY2026 · Mar 31, 2026Cost of Goods Sold
7.62BINRFY2026 · Mar 31, 2026Gross Profit
9.34BINRFY2026 · Mar 31, 2026Operating Income
566.00MINR5.94M · vs all stocks (USD)
Pre-tax Income
-783.00MINRFY2026 · Mar 31, 2026Income Tax Expense
-295.00MINRFY2026 · Mar 31, 2026Net Income
-488.00MINRFY2026 · Mar 31, 2026EBIT
-162.00MINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
2.33BINRFY2026 · Mar 31, 2026Other Operating Expenses
4.60BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
621.00MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
1.34BINRFY2026 · Mar 31, 2026Free Cash Flow
-139.00MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
96.00MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-783.00MINRFY2026 · Mar 31, 2026Other Non-cash Items
1.08BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
1.32BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-282.00MINRFY2026 · Mar 31, 2026Capital Expenditures
-1.48BINRFY2026 · Mar 31, 2026Purchase of Investments
0.00INRFY2026 · Mar 31, 2026Sale of Investments
4.00MINRFY2026 · Mar 31, 2026Other Investing Activity
12.00MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.46BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
1.35BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-1.31BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-848.00MINRFY2026 · Mar 31, 2026Common Dividends Paid
-123.00MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-936.00MINRFY2026 · Mar 31, 2026Shares Outstanding
123.30MSharesUpdated Jul 17, 2026Float Shares
38.08MSharesUpdated Jul 17, 2026% Held by Insiders
69.08%vs all stocks
% Held by Institutions
8.50%vs all stocks
Total Cash (MRQ)
193.00MINR2.03M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.56INRUpdated Jul 17, 2026Total Debt (MRQ)
6.83BINR71.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5721xCurrent Ratio (MRQ)
1.10xBook Value per Share (MRQ)
96.84INRUpdated Jul 17, 2026Total Assets
23.65BINR248.44M · vs all stocks (USD)
Total Current Assets
8.84BINRFY2026 · Mar 31, 2026Total Liabilities
11.67BINRFY2026 · Mar 31, 2026Total Non-current Assets
14.81BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
4.88BINRFY2026 · Mar 31, 2026Total Current Liabilities
6.79BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
96.00MINRFY2026 · Mar 31, 2026Other Short-term Investments
360.00MINRFY2026 · Mar 31, 2026Accounts Receivable
4.42BINRFY2026 · Mar 31, 2026Inventory
3.58BINRFY2026 · Mar 31, 2026Accounts Payable
2.67BINRFY2026 · Mar 31, 2026Short-term Debt
3.08BINRFY2026 · Mar 31, 2026Other Current Liabilities
199.00MINRFY2026 · Mar 31, 2026Long-term Debt
3.76BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
519.00MINRFY2026 · Mar 31, 2026Common Stock (Book)
247.00MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
11.99BINR125.91M · vs all stocks (USD)
52-Week Low
145.95INRUpdated Jul 17, 202652-Week High
354.75INRUpdated Jul 17, 202652-Week Change
-31.80%vs all stocks
Beta
0.3690xvs all stocks
50-Day MA
222.40INRUpdated Jul 17, 2026200-Day MA
288.70INRUpdated Jul 17, 2026Avg 10-Day Volume
60.03KSharesUpdated Jul 17, 2026Avg 30-Day Volume
35.30KSharesUpdated Jul 17, 2026Diluted EPS (TTM)
0.8000INRUpdated Jul 17, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.58Profit Margin: 0.01
Financial Health
Altman Z-Score 2.28: grey zoneSignificant
Altman Z-Score: 2.28
High earnings qualityNotable
Earnings Quality Score: 0.77
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface